EFFECT OF DONEPEZIL IN PATIENTS WITH PARKINSONâ??S DISEASE: A CLINICAL STUDY

EFFECT OF DONEPEZIL ON GAIT AND NEUROPHYSIOLOGICAL PARAMETERS IN PATIENTS WITH PARKINSONâ??S DISEASE: A PROSPECTIVE RANDOMISED CONTROL STUDY - DGPD

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/016000

Enrollment

Registered

2018-10-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Donepezil : i) Study group: Parkinsonâ??s disease patients who will be given donepezil treatment as 5 mg/day for initial 2 weeks and to increase to 10 mg/day for the remaining 6 weeks.

Eligibility

Inclusion criteria

Inclusion criteria: a) Age group 35- 80 years of either sex. b) Confirmed Diagnosis of Parkinsonâ??s disease as per UKPDS Brain Bank Criteria. c) Subjects with Hoehn and Yahr stages I to IV. d) Ability to walk without support or assistance for at least 25 meters at a stretch. e) Adequate visual acuity. f) The subjects must have a Miniâ??Mental State Examination (MMSE) of 18 or above and to be able to cooperate with the testing and be compliant with taking the experimental medications.

Exclusion criteria

Exclusion criteria: a) Patients with history of neurological conditions other than Parkinsonâ??s disease b) Factors affecting gait such as musculoskeletal disorders (particularly symptomatic hip, knee, lumbo-sacral spine and osteoarthritis), uncorrected vision disturbance, vestibular problems or any other health problem judged to interfere with participation. c) Medical problems that might be worsened by donepezil as tachycardia, bradycardia, arrhythmias, and peptic ulcer disease. d) Patients with major depression, hallucinations or other psychiatric disturbances. e) Patient with any implantable device.

Design outcomes

Primary

Measure	Time frame
a) To observe the effect of donepezil in 2 dimensional (2D) gait parameters using GAITRite electronic walkway. b) To investigate the changes in short latency afferent inhibition (SAI) after using donepezil. Timepoint: a) To observe the effect of donepezil in 2 dimensional (2D) gait parameters using GAITRite electronic walkway. b) To investigate the changes in short latency afferent inhibition (SAI) after using donepezil.	—

Measure

Time frame

a) To observe the effect of donepezil in 2 dimensional (2D) gait parameters using GAITRite electronic walkway. b) To investigate the changes in short latency afferent inhibition (SAI) after using donepezil. Timepoint: a) To observe the effect of donepezil in 2 dimensional (2D) gait parameters using GAITRite electronic walkway. b) To investigate the changes in short latency afferent inhibition (SAI) after using donepezil.

—

Secondary

Measure	Time frame
To compare the motor and cognitive parameters before and after using donepezil.Timepoint: To compare the motor and cognitive parameters before and after using donepezil.	—

Countries

India

Contacts

Public ContactYogesh Kumar

National Board of Examination

rishi_medicine@yahoo.com9874645445

Outcome results